Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Angiogenesis, Metastasis, and the Cellular Microenvironment

Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis11NIH U10 CA13539-27, subcontract 6641 (J. K.), NIH 1 R01 CA08895101-A1 (D. Y.), Pediatric Cancer Foundation, and Sorkin Gift Fund.Note: J. Huang and S. Z. Soffer contributed equally to this work.

Jianzhong Huang, Samuel Z. Soffer, Eugene S. Kim, Kimberly W. McCrudden, Joe Huang, Tamara New, Christina A. Manley, William Middlesworth, Kathleen O'Toole, Darrell J. Yamashiro and Jessica J. Kandel
Jianzhong Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Z. Soffer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugene S. Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kimberly W. McCrudden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamara New
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christina A. Manley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Middlesworth
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen O'Toole
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Darrell J. Yamashiro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica J. Kandel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    SK-NEP-1 xenografts are initially inhibited but resume growth during prolonged administration of anti-VEGF antibody, “metronome” topotecan, or combined agents. Cultured human SK-NEP-1 Wilms' tumor cells (106) were implanted intrarenally in athymic mice (n = 60). Animals were divided into four cohorts receiving MAbs, “metronome” topotecan, combined agents, or control vehicle beginning 1 week after implantation. Mice were monitored biweekly with calipers and euthanized when tumors reached 1.5 cm in greatest dimension. Tumor growth was delayed but not abolished by MAbs or topotecan administration, emerging at ∼60 days after tumor implantation. Growth in combination-treated tumors was also detected although in a more delayed fashion.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    Remodeling of endothelial and vascular MC compartments marks the tumors growing during antiangiogenic therapy. Xenografts, which grew during topotecan, MAbs, or MAbs + topotecan administration, displayed sparse but strikingly remodeled vasculature with irregular, large-caliber lumens and multiple layers of adhering vascular MC (most markedly in MAbs and MAbs + topotecan-treated tumors) in comparison with controls. Size bar = 200 μm.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    Diameters of remodeled vessels increased significantly in the tumors growing during antiangiogenic therapy. Mean diameters, measured using fluorescent immunostaining for αSMA, increased significantly in treated xenografts versus controls: 68% in topotecan, 97% in MAbs, and 96% in MAbs + topotecan tumors. Columns, mean diameter (μm); bars, SEM.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Proliferation of vascular MC in vessels of tumors recurring during antiangiogenic treatment. Double-label immunostaining, indicated by yellow areas (arrows) where αSMA (green fluorescent signal) and the proliferation marker phosphohistone H3 (red fluorescent signal) coincide, demonstrates active proliferation in the MC of a vessel supplying a tumor that resumed growth during anti-VEGF blockade. Cross section of MAbs tumor (A) and longitudinal view of vessels in combination-treated tumor (B) demonstrating thick layer of vascular MC with frequent proliferating nuclei. In comparison, surviving vessels in tumors inhibited by VEGF antagonism at 6 weeks were quiescent (data not shown). Size bar = 50 μm.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Expression of VEGF at the periphery of viable tumor islands contrasts with central expression of VEGFR2. Control tumors express all proangiogenic cytokines at the growing, well-vascularized periphery. Tumors that recur during antiangiogenesis grow as viable clusters or islands around vessels. The peripheral expression of VEGF indicates that the centers of these islands are relatively normoxic; the localization of VEGFR2 indicates the presence of central vessels, which presumably provide perfusion to the viable area of tissue. Size bar = 400 μm.

  • FIGURE 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 6.

    Expression of PDGFB, PDGFRβ, and EFNB2 are expressed in remodeled vessels of tumor growing during antiangiogenesis. In contrast, expression of PDGFB and PDGFRβ appear at the periphery of control tumors. Controls express markers of both venous and arterial specification (EPHB4 and the gene for ephrinB2, EFNB2), whereas EFNB2 was detected in remodeled vessels of treated tumors. Size bar = 400 μm.

  • FIGURE 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 7.

    Vascular remodeling results from altered expression of angiogenic cytokines during chronic suppression of angiogenesis. A. In control tumors, expression of VEGF supports sprouting of new vessel branches, which perfuse growing areas of tumor. PDGFB and VEGF cooperate to recruit MC to endothelial vessels. EphrinB2 and EphB4 are diffusely expressed, consistent with widespread arterial and venous specification in control vessels. B. When angiogenesis is chronically blocked, PDGFB expression by surviving vessels increases, which enhances endothelial stability and recruitment of MC. Vessel diameter increases significantly. Tumors resume growth, forming viable layers circumferential to vessels. Vascular expression of EphrinB2 increases, whereas EphB4 expression is relatively less, suggesting that EphrinB2 plays a role in stabilization or remodeling of these vessels.

PreviousNext
Back to top
Molecular Cancer Research: 2 (1)
January 2004
Volume 2, Issue 1
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis11NIH U10 CA13539-27, subcontract 6641 (J. K.), NIH 1 R01 CA08895101-A1 (D. Y.), Pediatric Cancer Foundation, and Sorkin Gift Fund.Note: J. Huang and S. Z. Soffer contr…
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis11NIH U10 CA13539-27, subcontract 6641 (J. K.), NIH 1 R01 CA08895101-A1 (D. Y.), Pediatric Cancer Foundation, and Sorkin Gift Fund.Note: J. Huang and S. Z. Soffer contributed equally to this work.
Jianzhong Huang, Samuel Z. Soffer, Eugene S. Kim, Kimberly W. McCrudden, Joe Huang, Tamara New, Christina A. Manley, William Middlesworth, Kathleen O'Toole, Darrell J. Yamashiro and Jessica J. Kandel
Mol Cancer Res January 1 2004 (2) (1) 36-42;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis11NIH U10 CA13539-27, subcontract 6641 (J. K.), NIH 1 R01 CA08895101-A1 (D. Y.), Pediatric Cancer Foundation, and Sorkin Gift Fund.Note: J. Huang and S. Z. Soffer contributed equally to this work.
Jianzhong Huang, Samuel Z. Soffer, Eugene S. Kim, Kimberly W. McCrudden, Joe Huang, Tamara New, Christina A. Manley, William Middlesworth, Kathleen O'Toole, Darrell J. Yamashiro and Jessica J. Kandel
Mol Cancer Res January 1 2004 (2) (1) 36-42;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results and Discussion
    • Materials and Methods
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Breast Stroma Instability
  • PRSS3/Mesotrypsin in Prostate Cancer
  • MUC1 Drives c-Met–Dependent Migration and Scattering
Show more Angiogenesis, Metastasis, and the Cellular Microenvironment
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement